Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYC300 + cyclophosphamide
- Development stage
- Phase 1
- Lead developer
- Eisai
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intramuscular (ZYC300), Intravenous Or Oral (cyclophosphamide)
01
Overview
ZYC300 + cyclophosphamide is a combination therapy consisting of ZYC300, a poly(lactide-co-glycolide) (PLG)-encapsulated plasmid DNA vaccine encoding the human tumor-associated antigen cytochrome P450 family member CYP1B1, and the chemotherapeutic agent cyclophosphamide. The combination is designed to enhance anti-tumor immune responses by using low-dose cyclophosphamide to selectively deplete regulatory T cells (Tregs), thereby potentiating the generation of robust and diverse T cell responses against tumor antigens presented by the ZYC300 vaccine. Cyclophosphamide acts as an alkylating agent with cytotoxic effects on rapidly dividing cells and immunomodulatory properties at lower doses. This regimen has been studied for its synergistic effect in cancer immunotherapy settings[1][3][7].
- Other names
- PLG-encapsulated CYP1B1 DNA vaccine + cyclophosphamide
02
Targets
CYP1B1 (Cytochrome P450 1B1)DNA
Beyond the preview
Go deeper on ZYC300 + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZYC300 + cyclophosphamide.